Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is a publicly traded Healthcare sector company. As of May 21, 2026, ZNTL trades at $3.68 with a market cap of $258.41M and a P/E ratio of -1.92. ZNTL moved +4.52% today. Year to date, ZNTL is +170.80%; over the trailing twelve months it is +189.84%. Its 52-week range spans $1.01 to $6.95. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces ZNTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zentalis Selects 400mg QD 5:2 Dose, Q1 Cash at $212M: Zentalis Pharmaceuticals ended Q1 2026 with $211.8 million in cash, funding operations into late 2027 and supports execution of DENALI and ASPENOVA trials. The company selected a 400mg QD 5:2 dose for its azenosertib monotherapy pivotal study and dosed the first patient in the Phase 3 ASPENOVA confirmatory trial.
| Metric | Value |
|---|---|
| Price | $3.68 |
| Market Cap | $258.41M |
| P/E Ratio | -1.92 |
| EPS | $-1.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.95 |
| 52-Week Low | $1.01 |
| Volume | 52 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.06M |
| Gross Margin | 0.00% |
7 analysts cover ZNTL: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.